Retinal Artery OcclusionCVO-RAONCT07482228
Long-term Clinical Outcomes After Retinal Artery Occlusion
An observational study of Retinal Artery Occlusion, run by Chonnam National University Hospital at 1 site in South Korea.
Trial summary
Retinal artery occlusion (RAO) is a rare but vision-threatening vascular disorder that is commonly caused by embolic events originating from the heart or carotid arteries. Patients with RAO are known to have an increased risk of subsequent cardiovascular and cerebrovascular events, including ischemic stroke and… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Retinal Artery Occlusion
- What is being tested?
- retinal artery occlusion
- How many people
- 15,000 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Mar 2026to 31 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients newly diagnosed with retinal artery occlusion (RAO) between 2010 and 2024 identified from the Korean National Health Insurance Service (NHIS) database.
Who may be able to join
- Patients newly diagnosed with retinal artery occlusion
Who cannot join
- Patients with a prior diagnosis of retinal artery occlusion before the study period.
- Patients diagnosed with giant cell arteritis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Chonnam National University Hospital
Gwangju, Gwangju, 61469
Seung Hun Lee, MD, PhD, 82-62-220-6246, lsh8602@naver.com
Seung Hun Lee, MD, PhD
About this study
Official title: Long-Term Cardiovascular and Cerebrovascular Outcomes After Retinal Artery Occlusion: A Nationwide Study
Retinal artery occlusion (RAO) is a rare but vision-threatening vascular disorder that is commonly caused by embolic events originating from the heart or carotid arteries. Patients with RAO are known to have an increased risk of subsequent cardiovascular and cerebrovascular events, including ischemic stroke and myocardial infarction. However, long-term outcomes and optimal medical treatment strategies for these patients remain insufficiently characterized.
The purpose of this nationwide population-based study is to investigate the incidence of long-term cardiovascular and cerebrovascular outcomes in patients diagnosed with retinal artery occlusion using the Korean National Health Insurance Service (NHIS) database. In addition, the study aims to evaluate the impact of various medical therapies, including antiplatelet agents, anticoagulants, and statins, on long-term clinical outcomes.
Read the detailed description
Retinal artery occlusion (RAO) is an acute retinal vascular disease that results in sudden and severe vision loss. RAO is typically classified into central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO), depending on the site of arterial obstruction. CRAO generally has a worse clinical prognosis compared with BRAO.
Previous studies have demonstrated that RAO is associated with systemic vascular diseases and an increased risk of ischemic stroke and other cardiovascular events. Despite its clinical significance, effective evidence-based treatment strategies for RAO remain unclear.
This study aims to evaluate the epidemiology and long-term cardiovascular outcomes of patients with RAO in Korea using the National Health Insurance Service (NHIS) database, which covers nearly the entire Korean population. Patients newly diagnosed with RAO between January 2010 and December 2024 will be identified.
This nationwide population-based study may help clarify the long-term prognosis of RAO and identify optimal medical treatment strategies for improving clinical outcomes in these patients.
- Conditions
- Retinal Artery Occlusion
- Being tested
- retinal artery occlusion
- Keywords
- RAO, CRAO, BRAO
- Medical subject headings
- Retinal Artery Occlusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
retinal artery occlusionOther
treatment for retinal artery occlusion
| Study group | Role | What they receive |
|---|---|---|
| Patients who underwent retinal artery occlusion | Among the total cohort, patients who underwent retinal artery occlusion were selected. Receives: Other: retinal artery occlusion | |
| Matched cohort | Among the total cohort, 1:6 age- and sex-matched subjects without retinal artery occlusion using a propensity score were generated. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of MACCE
major adverse cardiovascular and cerebrovascular event
Measured: up to 5 years
Secondary outcomes (8)
Occurrence of all-cause death
Death from any causes
Measured: up to 5 years
Occurrence of cardiac death
Death from cardiac causes
Measured: up to 5 years
Occurrence of myocardial infarction
Myocarrdial infarction
Measured: up to 5 years
Occurrence of revascularization
Percutaneous coronary intervention or coronary artery bypass grafting
Measured: up to 5 years
Occurrence of stroke
Ischemic or hemorrhagic stroke
Measured: up to 5 years
Occurrence of admission due to heart failure
Hospital admission due to heart failure
Measured: up to 5 years
Occurrence of atrial fibrillation
Newly developed atrial fibrillation
Measured: up to 5 years
Occurrence of major and clinically relevant non-major bleeding
Major and clinically relevant non-major bleeding
Measured: up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study start1 Mar 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinal Artery OcclusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 15,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chonnam National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Seung Hun Lee, Chonnam National University Hospital
- Investigators
- Seung Hun Lee, MD, PhD, Principal investigator, Chonnam National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07482228
- Sponsor's protocol ID
- CNUH-EXP-2026-013
- Acronym
- CVO-RAO
- Status last verified
- Mar 2026
- First submitted
- 16 Mar 2026
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-Term Cardiovascular and Cerebrovascular Outcomes After Retinal Artery Occlusion: A Nationwide Study
- ClinicalTrials.gov ID
- NCT07482228
- Acronym / sponsor ID
- CVO-RAO / CNUH-EXP-2026-013
- Conditions
- Retinal Artery Occlusion
- Keywords
- RAO, CRAO, BRAO
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 15,000 participants (estimated)
- Lead sponsor
- Chonnam National University HospitalUniversity, hospital or other
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Retinal artery occlusion (RAO) is a rare but vision-threatening vascular disorder that is commonly caused by embolic events originating from the heart or carotid arteries. Patients with RAO are known to have an increased risk of subsequent cardiovascular and cerebrovascular events, including ischemic stroke and myocardial infarction. However, long-term outcomes and optimal medical treatment strategies for these patients remain insufficiently characterized.
The purpose of this nationwide population-based study is to investigate the incidence of long-term cardiovascular and cerebrovascular outcomes in patients diagnosed with retinal artery occlusion using the Korean National Health Insurance Service (NHIS) database. In addition, the study aims to evaluate the impact of various medical therapies, including antiplatelet agents, anticoagulants, and statins, on long-term clinical outcomes.
Detailed description
Retinal artery occlusion (RAO) is an acute retinal vascular disease that results in sudden and severe vision loss. RAO is typically classified into central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO), depending on the site of arterial obstruction. CRAO generally has a worse clinical prognosis compared with BRAO.
Previous studies have demonstrated that RAO is associated with systemic vascular diseases and an increased risk of ischemic stroke and other cardiovascular events. Despite its clinical significance, effective evidence-based treatment strategies for RAO remain unclear.
This study aims to evaluate the epidemiology and long-term cardiovascular outcomes of patients with RAO in Korea using the National Health Insurance Service (NHIS) database, which covers nearly the entire Korean population. Patients newly diagnosed with RAO between January 2010 and December 2024 will be identified.
This nationwide population-based study may help clarify the long-term prognosis of RAO and identify optimal medical treatment strategies for improving clinical outcomes in these patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients who underwent retinal artery occlusion | – | Other: retinal artery occlusionAmong the total cohort, patients who underwent retinal artery occlusion were selected. |
| Matched cohort | – | –Among the total cohort, 1:6 age- and sex-matched subjects without retinal artery occlusion using a propensity score were generated. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients newly diagnosed with retinal artery occlusion (RAO) between 2010 and 2024 identified from the Korean National Health Insurance Service (NHIS) database.
Key inclusion criteria (1 listed)
- Patients newly diagnosed with retinal artery occlusion
Key exclusion criteria (2 listed)
- Patients with a prior diagnosis of retinal artery occlusion before the study period.
- Patients diagnosed with giant cell arteritis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| retinal artery occlusiontreatment for retinal artery occlusion | Other | Patients who underwent retinal artery occlusion |
Primary outcome
Occurrence of MACCE
Time frame: up to 5 years
major adverse cardiovascular and cerebrovascular event
8 secondary outcomes
Occurrence of all-cause death
Time frame: up to 5 years
Occurrence of cardiac death
Time frame: up to 5 years
Occurrence of myocardial infarction
Time frame: up to 5 years
Occurrence of revascularization
Time frame: up to 5 years
Occurrence of stroke
Time frame: up to 5 years
Occurrence of admission due to heart failure
Time frame: up to 5 years
Occurrence of atrial fibrillation
Time frame: up to 5 years
Occurrence of major and clinically relevant non-major bleeding
Time frame: up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Retinal Artery Occlusion
Not yet recruitingObservational study
The GEIR (Grupo español de Ictus Retina) Registry: Rationale and Design of the First Nationwide Multicentre Retinal Stroke Registry in Spain
Retinal Artery Occlusion, Central Retinal Artery Occlusion
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingObservational study
Patients With Type 2 Diabetes
Diabetes Mellitus Type 2
Not yet recruitingPhase 4
Emerging Indications for Hyperbaric Oxygen Treatment
Post-COVID-19 Condition, Ulcerative Colitis
Recruiting
New Non-invasive Modalities for Assessing Retinal Structure and Function
Ischemic Optic Neuropathy, Branch Retinal Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Seung Hun Lee, MD, PhD principal investigator
Chonnam National University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retinal Artery Occlusion, run by Chonnam National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Seung Hun Lee, MD, PhD (82-62-220-6246, lsh8602@naver.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurrence of MACCE (time frame: up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.